Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors

Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the...

Full description

Saved in:
Bibliographic Details
Main Authors Sullivan, Gerard M, Judd, Andrew S, Bruncko, Milan, Kunzer, Aaron R, Doherty, George, Wang, Xilu, Welch, Dennle S, Marin, Violeta L, Song, Xiaohong, Tao, Zhi-fu, Boghaert, Erwin R, Ackler, Scott L, Souers, Andrew J
Format Patent
LanguageEnglish
Published 06.08.2020
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
Bibliography:Application Number: US201916412729